Overview

Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer

Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
This study is being done to find out how safe TAS-108 is and how well TAS-108 works on recurrent or recurrent inoperable breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
SRI International
Collaborator:
Taiho Pharmaceutical Co., Ltd.
Treatments:
Estradiol